IP Library Granted Patent US 12,054,713
Granted Patent B2
US 12,054,713 · App. 17/107,699 · Granted Aug 6, 2024

Rotationally sequestered translators

Inventors: Daniel J. Kleinbaum (Redwood City, CA); Brian M. Frezza (Redwood City, CA); Brad Bond (Palo Alto, CA); Jonathan Leung (Sunnyvale, CA); George W. Fraser (Mountain View, CA)
Assignee: Emerald Therapeutics, Inc.
C12N15/113B82Y10/00C07H21/04C12N15/11C12Q1/68G06N3/002G06N3/123C12N2310/322C12N2310/334
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,054,713
App. No.
17/107,699
Granted
Aug 6, 2024
Kind
B2
Abstract

Provided are nucleic acid translators capable of carrying out logic operations with improved efficiency, maximized output and reduced off-target effects, in particular in a biological system. Methods of using these translators to transduce signal are also provided.

Claims (14)

1. A composition comprising a first, a second and a third nucleic acid complexes, wherein:

the first complex comprises a first, a second, a third and a fourth nucleic acid strands each comprising, sequentially, a first, a second and a third fragments and defined as B-W-D, C - W -Ā, D - Y -H, and G -Y-C, respectively, wherein each letter denotes a fragment and each string of letters connected by “-” denotes a strand, and wherein the first complex comprises a first duplex region (W:: W ) formed between the second fragments of the first and second strands, a second duplex region ( Y ::Y) formed between the second fragments of the third and fourth strands, a third duplex region (D:: D ) formed between the third fragment of the first strand and the first fragment of the third strand; and a fourth duplex region ( C ::C) formed between the first fragment of the second strand and the third fragment of the fourth strand;

the second complex comprises a first, a second, a third and a fourth nucleic acid strands each comprising, sequentially, a first, a second and a third fragments and defined as F-X-H, G - X -Ē, H - Z -Ī and J-Z-G, respectively, wherein the second complex comprises a first duplex region (X:: X ) formed between the second fragments of the first and second strands, a second duplex region ( Z ::Z) formed between the second fragments of the third and fourth strands, a third duplex region (H:: H ) formed between the third fragment of the first strand and the first fragment of the third strand; and a fourth duplex region ( G ::G) formed between the first fragment of the second strand and the third fragment of the fourth strand;

the third complex comprises a first, a second, a third, a fourth, a fifth and a sixth nucleic acid strands each comprising, sequentially, a first, a second and a third fragments and defined as C - Y -G, H -Y-D, G - Z - J , I-Z-H, J-Q-M and N - Q -Ī, respectively, wherein the third complex comprises a first duplex region ( Y ::Y) formed between the second fragments of the first and second strands, a second duplex region ( Z ::Z) formed between the second fragments of the third and fourth strands, a third duplex region (Q:: Q ) formed between the second fragments of the fifth and sixth strands, a fourth duplex region (G:: G ) formed between the third fragment of the first strand and the first fragment of the third strand; a fifth duplex region ( H ::H) formed between the first fragment of the second strand and the third fragment of the fourth strand, a sixth duplex region ( J ::J) formed between the third fragment of the third strand and the first fragment of the fifth strand, and a seventh duplex region (I::Ī) formed between the first fragment of the fourth strand and the third fragment of the sixth strand;

wherein, in the first complex, the first fragment (B) of the first strand, the third fragment (Ā) of the second fragment, the third fragment (H) of the third strand, and the first fragment ( G ) of the fourth strand are single-stranded; in the second complex, the first fragment (F) of the first strand, the third fragment (Ē) of the second fragment, the third fragment (Ī) of the third strand, and the first fragment (J) of the fourth strand are single-stranded; and in the third complex, the first fragment ( C ) of the first strand, the third (D) fragment of the second strand, the third fragment (M) of the fifth fragment, and the first fragment ( N ) of the sixth strand are single-stranded,

and wherein:

the third strand ( D - Y -H) of the first complex and the second strand ( H -Y-D) of the third complex have sequence complementarity to allow binding therebetween;

the fourth strand ( G -Y-C) of the first complex and the first strand ( C -Y-G,) of the third complex have sequence complementarity to allow binding therebetween;

the third strand ( H - Z -Ī) of the second complex and the fourth strand (I-Z-H) of the third complex have sequence complementarity to allow binding therebetween; and

the fourth strand (J-Z-G) of the second complex and the third strand ( G - Z -Ĵ) of the third complex have sequence complementarity to allow binding therebetween.

2. The composition of claim 1 , wherein each fragment is from about 5 bases to about 50 bases long.

3. The composition of claim 1 , wherein each fragment that is single-stranded is from about 5 bases to about 30 bases long.

4. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.

5. A cell comprising the composition of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2024
From: KLEINBAUM, DANIEL J.; FREZZA, BRIAN M.; BOND, BRAD; LEUNG, JONATHAN; FRASER, GEORGE W.
To: EMERALD THERAPEUTICS, INC.
Reel/Frame 066814/0714 →
Continuity (6)
Continuation 16664713 · Oct 25, 2019
Continuation 15470754 · Mar 27, 2017
Division 14721398 · May 26, 2015
Division 13801762 · Mar 13, 2013
Provisional Application 61754339 · Jan 18, 2013
Related Publication 20210102207A1 · Apr 8, 2021